CEL-SCI (CVM) Announces Initiation of New Sites for Multikine Phase III Clinical Study for Head and Neck Cancer in Taiwan
2/25/2013 11:54:56 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that its Taiwanese partner, Orient Europharma, has added two additional Taiwanese clinical centers in CEL-SCI’s Phase III head and neck cancer clinical trial for Multikine® (Leukocyte Interleukin, Injection), the Company’s flagship investigational immunotherapy. The first center is the China Medical University Hospital which is located in Taichung, Taiwan, and the second center is the Buddhist Tzu Chi General Hospital which is located in Hualian, Taiwan.
comments powered by